In vivo fluorescence imaging in the second near-infrared window (1.0-1.7 m) can afford deep tissue penetration and high spatial resolution, owing to the reduced scattering of long-wavelength 
Introduction
In vivo biological imaging in the second near-infrared window (NIR-II, 1.0-1.7 m) has attracted much interest recently [1] [2] [3] [4] [5] [6] [7] [8] owing to salient advantages over imaging in the visible (400-750 nm) and the conventional near-infrared (NIR, 750-900 nm) regions. Detecting longer wavelength photons in the NIR-II affords reduced photon scattering in biological tissues accompanied by lower autofluorescence, leading to higher spatial resolution at deeper tissue penetration depths. 9 To date, single-walled carbon nanotubes (SWNTs) [1] [2] [3] [10] [11] [12] [13] [14] , semiconducting quantum dots (QDs) 6, 7, [15] [16] [17] , rare-earth doped nanoparticles 8 and nanoparticles made of small organic molecules 18 are fluorophores used for fluorescence imaging in the NIR-II region. These NIR-II agents can be functionalized with hydrophilic molecules to afford biocompatibility for intravenous administration and can be gradually cleared out from the body without obvious acute or chronic toxicity in animal studies. 16, 19, 20 However, shortcomings of existing NIR-II fluorophores include relatively low fluorescence quantum yield 1, 8, 21 , unfavorably short emission wavelength 18 and potential toxicity due to heavy metals in QDs. 6, 7, [15] [16] [17] A much wider range of fluorophores could be developed to tackle these problems. An ideal fluorophore developed for NIR-II biological imaging should allow for tunable excitation and emission wavelengths in the > 1000 nm NIR-II region with a high fluorescence quantum yield and high biocompatibility.
Here we report the synthesis of conjugated polymers with intrinsic fluorescence > 1000 nm through donor-acceptor (D-A) alternating copolymerization, an effective way of synthesizing polymers with tunable bandgap energy in the NIR and at even longer wavelength regions. [22] [23] [24] [25] [26] [27] [28] [29] By copolymerization of an electron-donating monomer benzo [1,2- with fluorescence emission at ~1050 nm with a large Stokes shift of ~ 400 nm and a high fluorescence quantum yield of ~1.7%, much higher than the quantum yield of typical carbon nanotubes (~0.4%) used previously. 3 We non-covalently functionalize the polymer with a PEGylated surfactant to afford water solubility and biocompatibility. We successfully tune the emission wavelength of the conjugated polymer fluorophores from 1050 nm to 1350 nm, and demonstrate the first in vitro and in vivo biological imaging in the > 1000 nm window using conjugated polymer fluorophores.
Results
Synthesis of NIR-II Fluorescent pDA-PEG Nanoparticles. The pDA polymer was synthesized through a copolymerization reaction of two monomers, 1-(4,6-dibromo-3-fluorothieno [3,4- b]thiophen-2-yl)nonan-1-one and 2, 6-bis(trimethyltin)-4,8-bis (2-ethylhexyloxy)benzo [1,2- b;3,4-b']difuran. 26 Fluorine was introduced into the thienothiophene unit to tune the fluorescence to long wavelengths (Fig. 1) . The pDA polymer was characterized by 1 Atomic force microscopy (AFM) revealed the size distribution of pDA-PEG nanoparticles ( Fig. 2b) with an average size of 2.9 nm when dried on a silicon surface ( Supplementary Fig. 6 ). The UV-Vis-NIR absorption spectrum of the as-made pDA-PEG solution in water exhibited an absorption peak at 654 nm, while the fluorescence emission spectrum showed a main emission peak at 1047 nm, suggesting a large Stokes shift of ~ 400 nm (Fig. 2c) . The pDA copolymer has been reported to have red-shifted absorption and emission compared to the corresponding homopolymers, due to the formation of a charge-transfer structure between the electron donor and acceptor units. 26, 27, 30 The fluorescence quantum yield of pDA-PEG in a solution (Fig. 2d) under an excitation of 808 nm was ~ 1.7%, measured against a standard IR-26 dye as a reference 31, 32 ( Supplementary Fig. 7a-f , where the excitation of 808 nm was intentionally chosen to balance absorption and scattering to afford maximum penetration depth of excitation light for in vivo imaging). The quantum yield was much higher than that of typical nanotubes (~0.4%) ( Supplementary Fig. 7g-i) . The pDA-PEG exhibited high photostability in phosphate buffer saline (PBS) and fetal bovine serum with negligible decay under continuous excitation for 1 h (Fig. 2e-f and Supplementary Fig. 8 ). These results suggested pDA-PEG as an aqueous soluble, photo-stable and high brightness NIR-II fluorescent agent suited for biological imaging. This opened up the possibility of molecular imaging with conjugated copolymers in vitro and in vivo, which would not be attainable by structural imaging techniques such as ultrasound and optical coherence tomography (OCT).
35,36
Ultrafast Blood Flow Tracking with pDA-PEG in NIR-II. Next, we performed in vivo mouse blood vessel imaging by detecting the > 1000 nm fluorescence of intravenously injected pDA-PEG solutions. Owing to the bright fluorescence of pDA-PEG with a 4-fold higher quantum yield (1.7%) than nanotube fluorophores 3 (quantum yield ~0.4%), we were able to dynamically image and track real-time arterial blood flow in the mouse hindlimb with a much shorter exposure time (~20 ms) than previously possible (~ 100 ms) in the NIR-II window. showing oscillations between the highest instantaneous blood velocity of ~8 cm· s -1 and the lowest blood velocity of ~2 cm· s -1 , corresponding to the ventricular ejection (systolic) and ventricular relaxation (diastolic) phases respectively of a single cardiac cycle (Fig. 4c) . The observation of such a rapid periodic oscillation in the femoral blood velocity was entirely owed to the high time resolution of 20 ms, much shorter than the cardiac cycle of ~ 200 ms. The fast arterial blood flow (average speed ~ 4.36 cm· s -1 ) passed through the entire femoral artery (length ~2 cm) within two cardiac cycles (~400 ms). At longer times post injection, the same hindlimb imaged at 39 s post injection (p.i.) showed full perfusion of the injected NIR-II pDA-PEG fluorescent polymer into the femoral artery (Fig. 4d) .
To further glean the oscillating blood flow front with high time-resolution, we selected a region of interest (ROI) of the femoral artery and analyzed the NIR-II fluorescence intensity as a function of time (Fig. 5a) . We observed evenly spaced intensity humps over a linearly increasing baseline ( Fig. 5b) , with the humps corresponding to the systolic phases of cardiac cycles of the mouse and the increasing baseline due to increased overall perfusion of pDA-PEG fluorophore into the artery vessel. 3 By subtracting the linear rise from the intensity vs. time curve, we observed clear consecutive intensity spikes in the time course due to periodic ventricular ejections (Fig. 5c) . It is also interesting to note that the dots observed along the femoral artery in the baseline-subtracted images (Figs. 5f-h) were at fixed positions over time and corresponded to local higher NIR-II intensity regions along the femoral artery. These high intensity local regions were found to coincide with locations along the vessel with slightly larger vessel diameters (by ~20%) of the lumen measured with the vessel image. That is, more NIR-II pDA-PEG fluorophores in the blood were filled into a larger lumen and thus exhibited higher NIR-II intensity (Supplementary Fig. 9 ). From the NIR-II fluorescence oscillations with an average period of 206.7 ms per cardiac cycle (Fig. 5k) , we measured a heart rate of 290 beats per minute for the mouse, which agreed with previous results via cardiac gating. 38 Thus, the high-temporal and high-spatial resolution NIR-II imaging afforded by the high brightness of the conjugated polymer led to remarkably rich details of blood flows and cardiac cycles in vivo.
Discussion
In vivo fluorescence imaging of live animals in the NIR-II region benefits from deeper penetration of up to a few millimeters inside the body and reduced scattering of photons that scales inversely proportional with wavelength as ~ -w (w = 0.22-1.68) in biological tissues. 3, 9 Conjugated polymers have been widely used in organic solar cells, 26, 39 light-emitting diodes 40, 41 and organic electronics. 42, 43 Fluorescent imaging with conjugated polymers has been limited to emission wavelength < 900 nm. [44] [45] [46] Our current work developed the NIR-II agent with > 1000 nm fluorescence based on conjugated polymers for biological imaging both in vitro and in vivo. 47 The facile synthetic route of donor-acceptor copolymers could allow further tuning of the optical properties of the polymers through modifying the donor-acceptor structures (Supplementary Fig.   10 ) and the length of the copolymer. A more electron-donating donor and a more electronwithdrawing acceptor typically result in smaller band gap of the copolymer, 48 and a longer copolymer exhibits reduced band gap due to a greater delocalization of -electrons. 30 This could lead to a library of polymers with tunable excitation and emission wavelengths for NIR-II imaging (see Supplementary Fig. 10 for several polymers synthesized thus far). With such development, we envisage fluorophores with different emission wavelengths in the 1.0-1.7 m NIR-II window, allowing for multicolor molecular imaging of different biomarkers. Also, further improved penetration depth could be achieved in vivo by tuning the emission wavelength.
A salient advantage of the pDA-PEG polymer as an NIR-II fluorophore for in vivo live animal imaging is its much higher quantum yield (~1.7%) than SWNTs (~0.4%) previously used for hindlimb blood flow tracking. 3 This allows for much faster (20 ms exposure time vs. previous 100 ms) 3 video-rate imaging of dynamic changes in the blood flow labeled by NIR-II fluorophore, pushing the limit of temporal resolution to a previously unattainable level of > 25 fps (the instrument frame rate limit is 50 fps due to an overhead time of 19 ms). Although the pDA-PEG polymer has similar quantum efficiency (~1.7%) to nanoparticles of small organic molecules (~1.8%), 18 since the major peak of the small organic molecule nanoparticles is located at ~920 nm while the major peak of pDA-PEG polymer is at ~1050 nm, the pDA-PEG polymer has a greater portion of emitted photons in the >1000 nm NIR-II region (~70%) than the small molecule nanoparticles (~40%). 18 Taken together, the high fluorescence quantum yield, redshifted fluorescence emission in the NIR-II region and low density of the pDA polymer require 10~100× lower mass dose of injection than previous NIR-II fluorophores (such as SWNTs 1-3,9-12 , QDs 6,7,15-17 , rare-earth doped nanoparticles 8 and nanoparticles incorporating organic molecules 18 ) to reach the same in vivo imaging quality, and allow for dynamic fluorescence imaging with much shorter exposure time and higher temporal resolution. This high temporal resolution well exceeds the heart rate of mice (~5 beats per second, or ~ 200 ms per cycle) by 5 times, eliminating the need for cardiac gating typically required for low-frame-rate cardiovascular imaging techniques. 38, 49 Previous fluorescence imaging and tracking of blood flow usually require the removal of scattering tissue over the vessels of interest to afford higher spatial resolution, and gating devices to eliminate image blurring due to cardiac and respiratory motions on a faster time scale than the temporal resolution of image acquisitions (~10 fps). 38, 50 Ultrasound imaging and optical coherence tomography (OCT) with ultrafast image acquisition rate (kHz~MHz) have shown the advantages of measuring fast blood flow and cardiac cycles, [51] [52] [53] but the spatial resolution (in the 10 m ~ 1 mm range) and signal-to-noise ratio are sub-optimal due to long wavelengths 54 and speckles. 55, 56 Here, by utilizing NIR-II fluorescence with reduced tissue scattering and an ultrafast frame rate of >25 fps, we have enabled simultaneous blood velocity and cardiac cycle measurements as well as high resolution imaging of blood vessels 1-2 mm deep under otherwise highly scattering skin tissues. 57 We have also proved the concept that the polymer-based NIR-II fluorophores can be used to track blood flow in capillaries with sub-10 m diameters ( Supplementary Fig. 11a ), which are well below the spatial resolutions of traditional ultrasound and OCT. Based on the capillary blood flow tracking images, we measured the capillary blood velocity to be ~55.2 m· s -1 ( Supplementary Fig. 11b ), in good agreement with previous studies. 58, 59 The dynamic range of blood velocity measurement in our NIR-II imaging system using the pDA fluorophores is derived as 0 to 640 mm/s based on the brightness of the fluorophore and the detector sensitivity (Supplementary Note 1). In addition, we have shown that the pDA-PEG fluorophores can be used to track regional blood flow and redistribution as a result of increased metabolic demand after heat-induced inflammation of the tissue ( Supplementary Fig. 12 ), providing a direct diagnostic tool for visualizing the metabolic difference of the tissue.
The heavy-metal-free nature of fluorescent conjugated polymers bodes well for potentially low toxicity agents for in vivo applications. 60 In a cellular toxicity study, we found that the toxicity of pDA-PEG nanoparticles depended on the surfactant coating, and a surfactant with branched PEG exhibited alleviated toxicity (see Methods). The mice injected with pDA-PEG were monitored over a period of up to 2 months without showing obvious toxic effects or health problems. We also attempted tuning the size of the pDA-PEG nanoparticles and obtained the smallest pDA-PEG with an average hydrodynamic size of < 6 nm ( Supplementary Fig. 13 , and also see Methods for more information). Systematic investigation is required to study the long term fate and toxicology of pDA-PEG nanoparticles, which is beyond the scope of the current work.
Real-time hemodynamic imaging could be of central importance to better understanding various cardiovascular diseases and designing treatment strategies. 61 An ideal NIR-II fluorescent agent capable of achieving hemodynamic imaging with high spatial and temporal resolutions should have tunable emission wavelength in the >1000 nm region to minimize tissue scattering, high fluorescence quantum efficiency (> 5%) for ultra-short imaging exposure time. The current work opens up future research to achieve these goals, and could eventually lead to NIR-II fluorescence agents suitable for clinic use.
Methods
Synthesis of pDA copolymer. The synthesis of monomers M1 and M2 can be found in previous publications. [62] [63] [64] For the synthesis of the pDA copolymer, 0.091 g of monomer M1 (0.2 Characterizations of monomers and pDA copolymer. All compounds, including the monomers M1 and M2, and the pDA copolymer, were characterized by nuclear magnetic resonance (NMR) spectroscopy. The 1 H NMR and 19 F NMR spectra were measured on a Bruker AV-400 spectrometer at room temperature. Chemical shifts were described as  values (ppm), where tetramethylsilane (TMS) was used as an internal reference. Splitting patterns were labeled as s (singlet), d (doublet), t (triplet), m (multiplet) and br (broad). As such, the NMR spectral assignments for the two monomers M1 and M2, as well as the product polymer, are given as follows, a 1000-nm short-pass filter (Thorlabs), an 1100-nm short-pass filter (Omega) and a 1300-nm short-pass filter (Omega). The emission was collected in the transmission geometry with a 900-nm long-pass filter (Thorlabs) to reject the excitation light and the emission spectrum was taken in the 900-1500 nm region. The same absorption and emission measurements were carried out for pDA-PEG polymers and SWNTs in aqueous solutions too. Then all emission spectra of both the reference and the samples were corrected after raw data acquisition to account for the detector sensitivity profile and the extinction profiles of the filters, and integrated in the 900-1500 nm NIR-II region. The definition of quantum yield dictates that all emitted photons should be taken into account for quantum yield measurement. 65 In our quantum yield measurements, since an 808-nm laser is used, ideally the integration of the emission spectra should start from 809 nm to cover the complete emission band; however, due to the limited choice of excitation and emission filters, we started the integration from 900 nm, which would give an underestimated quantum yield. Nonetheless, this underestimation would not be too much since one could see from the emission spectra that the emission dropped rapidly below 950 nm, meaning there would not be too much fluorescence emission under 900 nm. The integrated NIR-II fluorescence intensity was plotted against absorbance at the excitation wavelength of 808 nm and fitted into a linear function. Two slopes, one obtained from the reference of IR-26 in DCE and the other from the sample (pDA-PEG or SWNT), were employed in the calculation of the quantum yield of the sample, based on equation (1) as follows,
where and are the refractive indices of water and DCE, respectively. Isoflurane. Then the hair over the hindlimb skin was carefully removed using Nair to avoid causing wounds to the skin. Tail vein injection of the pDA-PEG contrast agent was carried out in dark and synchronized with the camera that started continuous image acquisition simultaneously.
The injected dose was a 200 L bolus of the pDA-PEG in a 1× PBS solution at a mass concentration of 0.25 mg· mL -1 . During the time course of imaging the mouse was kept anesthetized by a nose cone delivering 1.5 L· min -1 O 2 gas mixed with 3% Isoflurane.
Ultrafast video-rate NIR-II vessel imaging.
Video-rate NIR-II vessel imaging was done in a similar manner as our previous publication. 3 In brief, imaging was carried out on a homebuilt and filtered by an 850-nm and a 1000-nm shortpass filter (ThorLabs). The power density of the excitation laser at the imaging plane was 140 mW· cm -2 , significantly lower than the reported safe exposure limit of 329 mW· cm -2 at 808 nm. 67 The emitted fluorescence from the mouse was allowed to pass through a 900 nm and a 1000 nm long-pass filter (Thorlabs) and to be focused hydrodynamic size on initial pDA concentration and PEG molecular weight is plotted in Supplementary Fig. 13 , showing that both smaller PEG and lower initial concentration of pDA favor the formation of smaller pDA-PEG nanoparticles in aqueous solution. However, it is noteworthy that DLS was not able to discriminate the 'empty' nanoparticles without any pDA molecules loaded inside, and therefore the size distribution of the measured hydrodynamic diameters below ~4 nm could be due to the micelles formed by the DSPE-mPEG surfactants only. DSPE-2k-mPEG DSPE-5k-mPEG
